Our 2021 Masterclasses has been broken down into individual on-demand lectures which are available for mix-and-match purchase. This ensures we are giving you access to the most relevant and affordable content. Lectures are £20 each.
-
What is Value?
Buy this lecture | FREEMartina Garau
Director | OHEAssociated Masterclass: Exploring Value: Novel Elements for Breakthrough Treatment.
Lecture duration: 05:47
- Exploring the expanded and actionable definition of value
- Discussing how broader value elements resonate with decision makers
- Understanding the practical and policy challenges faced by adopting broader value elements
-
What are the novel and established sources of value?
Buy this lecture | £20Professor Adrian Towse
Director Emeritus and Senior Research Fellow | OHEAssociated Masterclass: Exploring Value: Novel Elements for Breakthrough Treatment.
Lecture duration: 17:19
- Exploring a brief history of established sources of value
- Analysing novel value elements and what they entail
- Discussing which value elements should be considered
-
Methods and practice to consider broader value elements in decision making
Buy this lecture | £20Martina Garau
Director | OHEAssociated Masterclass: Exploring Value: Novel Elements for Breakthrough Treatment.
Lecture duration: 17:01
- Exploring the need for an aggregation method for multiple value elements
- Outlining the implications of cost effectiveness benchmarks
- Discussing the continuum of decision making approaches from deliberative to quantitative with real-world examples
-
What do health systems aim to maximise?
Buy this lecture | £20Patricia Cubi-Molla
Senior Principal Economist | OHEAssociated Masterclass: Patient Outcomes: Measuring What Matters to Patients.
Lecture duration: 18:54
- Public sector spending and research allocation
- Healthcare sector spending through measuring patient preference
- Health technologies spending through measuring outcomes
-
Going beyond patients’ health-related quality of life – wellbeing and carers health-related quality of life
Buy this lecture | £20Dr David Mott
Principal Economist | OHEAssociated Masterclass: Patient Outcomes: Measuring What Matters to Patients.
Lecture duration: 19:35
- Outlining when and how the quality of life of carers should be measured
- Discussing the potential impact of carer quality of life measurement on HTA
- Exploring broader outcome measurements and their scope for use in HTA
-
Alternative approaches to measure patient outcomes (within the QALY framework)
Buy this lecture | £20Dr Chris Sampson
Principal Economist | OHEAssociated Masterclass: Patient Outcomes: Measuring What Matters to Patients.
Lecture duration: 19:52
- Exploring alternative generic measures for patient outcomes
- Outlining condition-specific measures and their potential advantages
- Introducing bolt-ons methods
-
The ‘patient voice’ in health technology assessment
Buy this lecture | £20Dr Chris Skedgel
Director | OHEAssociated Masterclass: The Patient Voice: Capturing Patient Preferences in Decision-Making.
Lecture duration: 13:40
- Explaining patient preferences in HTA
- Discussing empirical evidence around the role of patient preferences in HTA
- Outlining the future of the patient voice in HTA
-
How are patient preferences elicited?
Buy this lecture | £20Dr David Mott
Principal Economist | OHEAssociated Masterclass: The Patient Voice: Capturing Patient Preferences in Decision-Making.
Lecture duration: 19:57
- Methodologies used to elicit quantitative patient preference data
- The typical stages of a quantitative patient preference study
- The type of insights that can be obtained from quantitative patient preference data
-
Research and Development (R&D) for OMPs
Buy this lecture | £20Professor Adrian Towse
Director Emeritus and Senior Research Fellow | OHEAssociated Masterclass: Innovation for Small Populations: What Should We Pay for?
Lecture duration: 20:16
- Is Market Exclusivity (ME) needed to incentivise the Research & Development (R&D) of Orphan Medical Products (OMPs)?
- Are R&D costs for individual OMPs lower than those for medicines for more common conditions?
- What is a fair price for OMPs?
-
HTA for Orphan Medicinal Products (OMPs)
Buy this lecture | £20Dr Chris Skedgel
Director | OHEAssociated Masterclass: Innovation for Small Populations: What Should We Pay for?
Lecture duration: 19:32
- Are health conditions been salami-sliced to drive exceptionalism?
- Can evidence in support of Health Technology Assessment (HTA) submissions for OMPs meet the same standards as medicines for more common conditions?
- What is society willingness to prioritise treatments for rare conditions?
-
Bridging the gap between regulatory and reimbursement
Buy this lecture | £20Professor Lotte Steuten
Vice President | OHEAssociated Masterclass: Adaptive Pathways: Generating Evidence of Value.
Lecture duration: 22:28
- Elements driving uncertainty at an early stage of a treatment introduction
- Using surrogate endpoints in clinical trials
- How different types of uncertainty can be addressed, including conditional reimbursement schemes
-
Are Adaptive Pathways always the answer?
Buy this lecture | £20Professor Adrian Towse
Director Emeritus and Senior Research Fellow | OHEAssociated Masterclass: Adaptive Pathways: Generating Evidence of Value.
Lecture duration: 20:55
- Implications of accelerated approval for payer uncertainty
- Application of the value of information approach to inform optimal use of risk sharing schemes
- When companies should actively seek an AP
-
Adaptive Pathways: insights from the experience in Europe and the UK.
Buy this lecture | £20Isobel Firth
Senior economist | OHEAssociated Masterclass: Adaptive Pathways: Generating Evidence of Value.
Lecture duration: 17:36
- Accelerated Pathways (AP) introduced by the EMA and MHRA
- What APs mean to development and access to medicines
- Examples of early access in Europe